New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
11:08 EDTTROVTrovagene says diagnostic platform demonstrates ability to monitor mutations
Clinical study results presented at the American Association for Cancer Research Annual Meeting demonstrate the ability of Trovagene's molecular diagnostic platform to detect and monitor BRAF V600E mutations in cancer patients, the company said. Of the 33 patients enrolled in the study, Trovagene's BRAF V600E oncogene mutation assay was able to identify the mutation in 29 patients, or 88%, at any time point during the study, demonstrating a high level of concordance with tissue biopsy. In addition, 25 of the 33 patients, or 76%, were positively identified for the mutation with their first urine sample. Mark Erlander, Ph.D., chief scientific officer of Trovagene, stated, "The concordance shown between our platform and tissue biopsy in this study are encouraging, especially when we consider that different patients will show response to treatments at different times."
News For TROV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2015
16:09 EDTTROVTrovagene reports presentation of field experience analysis results with PCM
Trovagene announced the presentation of results from a field experience analysis featuring the use of its Precision Cancer Monitoring, or PCM, platform to accurately identify mutational status, which can be critical for physicians to determine appropriate therapy for patients. Mark Erlander, Ph.D. chief scientific officer of Trovagene is delivering the results today in an oral presentation titled CLIA Laboratory Testing of Urinary BRAF V600E DNA mutations: Application in the Management of Patients with Histiocytic Diseases at the 3rd Annual Erdheim-Chester International Medical Symposium, MD Anderson Cancer Center in Houston, Texas. The ability to quickly and accurately determine BRAF mutational status is very important to our patients with histiocytic disease when assessing therapeutic options," stated Filip Janku, M.D. Ph.D., of the University of Texas MD Anderson Cancer Center. "In patients that test positive for the mutation, the use of a BRAF inhibitor can offer a prolonged benefit that significantly improves their quality of life. We are encouraged by the recent advances in molecular diagnostic testing that can enable fast, accurate and non-invasive testing for our patients." Antonius Schuh, Ph.D., CEO of Trovagene, stated, "These data again demonstrate the ability of our urinary liquid biopsy platform to determine and monitor mutational status in patients when tissue biopsy is either inconclusive or unavailable. We are pleased to support the underserved histiocytic patient population for whom determining BRAF mutational status can be critical for therapeutic selection and improving treatment outcomes."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use